Loading clinical trials...
Loading clinical trials...
CIRCuiTS MS: Improving Cognitive Recovery in Multiple Sclerosis
This study aims to find out whether an adapted version of an existing cognitive rehabilitation program, CIRCuiTS (https://www.circuitstherapyinfo.com), can be used to improve everyday thinking skills for people with Multiple Sclerosis (MS). People living with MS have worked with the study's researchers to adapt CIRCuiTS to meet their needs. They shared the thinking challenges they experience and suggested changes to the program's content and how it is delivered. This study will test whether this adapted version can be delivered practically to people with MS in a trial setting and explore its potential benefits. The findings will help plan a larger trial testing how effective CIRCuiTS is in helping people with MS. Twenty-four people with MS will take part in this pilot trial. Each person will be randomly assigned to start the program either right away or after a 13-week wait. The therapy program involves up to 36 hours of therapist-led and independent sessions over 12 weeks in which the participant builds thinking skills through developing personal strategies for carrying out digital versions of tasks they find challenging. The practicality of delivering the program to people with MS will be judged based on whether problems arise in the trial, such as not being able to recruit enough people or participants not liking it. To explore its potential benefits, the study will check for improvements in progress toward personal goals, thinking abilities, emotional well-being, chronic tiredness, and daily living skills after the therapy. If delivering CIRCuiTS to people with MS is found to be both practical and acceptable to participants, the findings of this trial will be used to design a larger-scale trial of its effectiveness. Ultimately, the goal of this project is to improve the quality of life of people living with cognitive difficulties related to MS.
Objectives The primary goal of this study is to assess the practical aspects of the research to determine whether a larger, fully-scale trial will be viable and acceptable. A feasibility decision will be reached by judging whether a suite of "Go"/"No-Go" thresholds associated with the primary outcome measures have been passed. Additionally, acceptability will be explored through qualitative analysis of participant exit interviews. The secondary goal is to explore the potential that a larger trial will show that the program helps people with MS in meaningful ways. Specifically, the study will examine whether the cognitive remediation program: 1. Helps participants meet their personal goals 2. Improves participants' cognitive function (how they think and think about thinking) 3. Improves participants' mood (specifically feelings of anxiety and depression, which are common in people with MS) 4. Helps reduce the severe fatigue that many people with MS experience 5. Affects participants' ability to carry out everyday activities, such as managing tasks at home, working, and engaging in social and leisure activities. These factors will be evaluated through assessing change in the secondary outcome measures after therapy.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
King's College London
London, East of England, United Kingdom
Start Date
July 17, 2025
Primary Completion Date
September 15, 2026
Completion Date
September 15, 2026
Last Updated
July 22, 2025
24
ESTIMATED participants
CIRCuiTS-MS
BEHAVIORAL
Lead Sponsor
King's College London
Collaborators
NCT06276634
NCT07225504
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06809192